• Home
  • About Us
  • Contact US !
Incitasecurity
  • Home
  • Finance
  • Gadgets
  • Education
  • Latest Internet News
  • Technology
  • Social Media
  • Blogging
  • CrossFit
  • UpComing Car
No Result
View All Result
  • Home
  • Finance
  • Gadgets
  • Education
  • Latest Internet News
  • Technology
  • Social Media
  • Blogging
  • CrossFit
  • UpComing Car
No Result
View All Result
Incitasecurity
No Result
View All Result
Home Uncategorized

Jimmy Carter Credits Cancer Drug Keytruda For Vanishing His Brain Tumors

onkar by onkar
December 10, 2015
in Uncategorized
0
VIEWS
Share on FacebookShare on Twitter

Former President Jimmy Carter

Former President Jimmy Carter announced that recent brain scans found no evidence of cancer. After being diagnosed with melanoma, a very serious type of cancer affecting his liver and brain, he credited Keytruda, a new cancer drug, for shrinking his brain tumors entirely.

Keytruda or Pembrolizumab is a new immunotherapy drug by pharmaceutical giant Merck. The U.S. Food and Drug Administration approved it as a new treatment drug for patients suffering from melanoma and lung cancer.

“My most recent MRI brain scan did not reveal any signs of the original cancer spots nor any new ones. I will continue to receive regular 3-week immunotherapy treatments of pembrolizumab,” former President Jimmy Carter, the 39th President of the United States and a Nobel Prize winner in 2002 said.

Carter, 91 years old, announced the news of his recovery during a service of a Sunday school class at Maranatha Baptist Church in Georgia. In August, he revealed that he was diagnosed with melanoma as doctors spotted four tumors in his brain and a large one in his liver.

Health experts, however, say it is not clear if the drug itself shrank the tumors in his brain. Apparently, Carter underwent radiation therapy for his brain tumors and had the large tumor in his liver surgically removed.

The drug targets the activity of genes called PD-1 and PD-L1. When these cells interact, they let some tumor cells become invisible to the immune system preventing their destruction. Dubbed as a monoclonal antibody or PD-1 inhibitor, it alters this invisibility effect tumors use to evade attack by immune cells.

In a recent update, Merck’s Keytruda shows promise in the treatment of blood cancer multiple melanomas. In the clinical trial conducted, they tested the drug in patients whose cancer progressed despite undergoing a battery of treatment options. The overall response rate of patients was 76 percent which means that most patients had reduction in cancer cells.

Aside from melanoma and lung cancer, scientists tested the drug in 30 tumor types. In fact, it recently received a breakthrough designation from U.S. FDA for its effect on colorectal cancer.

[“source-techtimes”]

Tags: Cancer Drug KeytrudaFor Vanishing His Brain TumorsJimmy Carter Credits
Previous Post

Prostate Cancer Treatment May Up Risks For Alzheimer’s

Next Post

Nearly 200 People Sickened In Seattle Norovirus Outbreak

Next Post
Nearly 200 People Sickened In Seattle Norovirus Outbreak

Nearly 200 People Sickened In Seattle Norovirus Outbreak

Recent Post

  • Diane: Unleashing Strength and Stamina with CrossFit’s Intense WOD
  • Mastering the Ground to Overhead: Unlock Your Full CrossFit Potential
  • Crushing the Challenge: Conquering the CrossFit Workout ‘Diane’ for Ultimate Strength and Fitness
  • Building Strength and Community: Unleashing the Power of CrossFit Sioux Falls
  • Exploring the CrossFit Monthly Cost: Breaking Down Membership Fees and Value
  • Comparing CrossFit Physiques to Traditional Gym Builds in Female Athletes: Exploring Strength, Stamina, and Aesthetics
  • Cracking the Code: Unveiling the CrossFit Chipper Workout
  • Revitalize Your Fitness Journey with Acid Bath CrossFit: Embrace the Intensity and Achieve Peak Performance
  • The Cost of CrossFit: Pricing and Membership Options Revealed
  • Mastering the Split Jerk: Unleashing Power and Precision in CrossFit
Incitasecurity

© 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.

Navigate Site

  • Home
  • About Us
  • Contact US !

Follow Us

No Result
View All Result
  • Home
  • Finance
  • Gadgets
  • Education
  • Latest Internet News
  • Technology
  • Social Media
  • Blogging
  • CrossFit
  • UpComing Car

© 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.